Results from Orviglance comparison study to gadolinium presented at RSNA 2021

2021-12-01
PDF
PDF
Presentation

Ascelia Pharma AB (publ) (ticker: ACE) today presented results at the world’s largest radiology conference, RSNA, in Chicago, Illinois from the study in which the investigational contrast agent Orviglance® was compared against a gadolinium-based contrast agent.

As communicated earlier, the comparison study versus the gadolinium contrast agent showed that MRI enhanced with the contrast agent Orviglance (former working name Mangoral) was as effective as the gadolinium contrast agent gadobenate dimeglumine (Multihance) in terms of visualization of lesions and number of detected lesions in the liver. The results also showed that Orviglance-enhanced MRI provides improved efficacy in terms of lesion detection and visualization compared to MRI without a contrast agent.

The presentation today at RSNA shows specifically the results of the efficacy parameters in the study including:

  • Number of lesions detected
  • Size of the detected lesions
  • Lesion border delineation
  • Lesion contrast compared to liver

The results showed that a higher number of liver lesions was detected by all three independent readers for Orviglance compared to gadolinium. All three readers were also able to see smaller lesions with Orviglance compared to gadolinium.

With respect to lesion border delineation and lesion contrast to liver, two out of three readers reported higher scores to Orviglance compared to gadolinium.

While the efficacy parameters show higher scores for Orviglance, it is important to notice that this crossover study was comprised only of 20 patients with liver metastases and the higher scores for Orviglance vs. gadolinium are not statistically sufficient to conclude that Orviglance is superior to gadolinium.

“We are very pleased to have presented the study as an oral paper presentation at the prestigious Radiological Society of North America’s radiology conference, RSNA. The study provides robust evidence of the diagnostic value that Orviglance can offer once it is available to patients and physicians. Orviglance is being developed to address the unmet medical need of patients with poor kidney function who require liver imaging, and it is very encouraging that Orviglance is as effective as a gadolinium contrast agent, said Carl Bjartmar, Chief Medical Officer at Ascelia Pharma.